Loading...
XSWXSFZN
Market cap4.71bUSD
Dec 20, Last price  
981.00CHF
1D
0.72%
1Q
-14.70%
Jan 2017
360.56%
Name

Siegfried Holding AG

Chart & Performance

D1W1MN
XSWX:SFZN chart
P/E
37.31
P/S
3.31
EPS
26.29
Div Yield, %
0.34%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
9.87%
Revenues
1.27b
+3.41%
321,361,000318,335,000299,766,000318,256,000288,745,000283,041,000314,409,000328,095,000367,800,000374,940,000315,282,000480,571,000717,729,000750,468,000794,297,000833,514,000845,062,0001,102,423,0001,229,518,0001,271,494,000
Net income
113m
-27.94%
16,393,00036,534,00032,392,00049,710,000-74,834,000-35,263,000-16,243,0009,599,00020,868,00053,851,00038,556,00039,100,00027,906,00039,732,00056,310,00053,147,00060,867,00095,600,000156,490,000112,774,000
CFO
209m
+55.09%
72,178,00047,953,00052,142,00062,657,00022,294,00045,465,00057,677,00031,810,00054,322,00067,529,00024,642,00023,075,00057,113,00084,632,000106,001,00055,858,000105,284,000112,357,000134,505,000208,608,000
Dividend
May 03, 20243.6 CHF/sh
Earnings
Feb 18, 2025

Profile

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
URL
https://www.siegfried.ch/
IPO date
Jan 01, 1973
Employees
3,633
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,271,494
3.41%
1,229,518
11.53%
1,102,423
30.45%
Cost of revenue
1,104,412
997,165
969,823
Unusual Expense (Income)
NOPBT
167,082
232,353
132,600
NOPBT Margin
13.14%
18.90%
12.03%
Operating Taxes
37,682
62,284
30,927
Tax Rate
22.55%
26.81%
23.32%
NOPAT
129,400
170,069
101,673
Net income
112,774
-27.94%
156,490
63.69%
95,600
57.06%
Dividends
(14,438)
(13,535)
(12,630)
Dividend yield
0.39%
0.51%
0.33%
Proceeds from repurchase of equity
(5,467)
(23,008)
(11,158)
BB yield
0.15%
0.87%
0.29%
Debt
Debt current
55,541
19,871
Long-term debt
445,000
590,000
560,000
Deferred revenue
(1)
Other long-term liabilities
159,735
162,099
219,179
Net debt
388,060
553,332
506,578
Cash flow
Cash from operating activities
208,608
134,505
112,357
CAPEX
(127,441)
(115,208)
(113,397)
Cash from investing activities
(146,864)
(103,715)
(250,100)
Cash from financing activities
(94,750)
(10,683)
156,242
FCF
84,233
90,552
(244,896)
Balance
Cash
56,626
91,618
72,966
Long term investments
314
591
327
Excess cash
30,733
18,172
Stockholders' equity
731,622
813,040
686,913
Invested Capital
1,442,868
1,432,294
1,369,224
ROIC
9.00%
12.14%
8.49%
ROCE
11.42%
15.75%
9.48%
EV
Common stock shares outstanding
4,300
4,313
4,340
Price
859.50
40.10%
613.50
-31.03%
889.50
36.53%
Market cap
3,696,117
39.67%
2,646,281
-31.45%
3,860,514
38.04%
EV
4,084,074
3,199,613
4,367,092
EBITDA
248,435
314,301
215,716
EV/EBITDA
16.44
10.18
20.24
Interest
9,300
7,574
3,861
Interest/NOPBT
5.57%
3.26%
2.91%